Robert Bissonnette, MD: Discussing the First Oral IL-23 Inhibitor for Psoriasis

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.

Related Keywords

Robert Bissonnette ,Innovaderm Research ,Chief Executive Officer ,Psoriasis ,Pso ,Plaque ,Jnj 2113 ,Coral ,Il 23 ,Inhibitor ,Bissonnette ,Nejm ,